Plasmatic Levels of HSP90α at Diagnosis: A Novel Prognostic Indicator of Clinical Outcome in Advanced Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors Plus Chemotherapy
BackgroundThe purpose of this study was set to investigate the prognostic role of plasmatic levels of heat shock protein 90 alpha (HSP90α) at diagnosis in advanced lung cancer patients treated with Programmed cell death protein 1 (PD-1)/Programmed cell death-Ligand protein 1 (PD-L1) inhibitors plus...
Enregistré dans:
Auteurs principaux: | Shubin Chen, Qitao Yu, Shaozhang Zhou |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Frontiers Media S.A.
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/c7c859bebc814d268df00627ae90fe83 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Treatment-Related Adverse Events with PD-1 or PD-L1 Inhibitors: A Systematic Review and Meta-Analysis
par: Yixi Zhang, et autres
Publié: (2021) -
Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges
par: Zhitao Li, et autres
Publié: (2021) -
Single-cell RNA sequencing to characterize the response of pancreatic cancer to anti-PD-1 immunotherapy
par: Jing Zhou, et autres
Publié: (2022) -
Clinicoprognostic and Histopathological Features of Guttate and Plaque Psoriasis Based on PD-1 Expression
par: Chang-Jin Jung, et autres
Publié: (2021) -
Stomach cancer. Clinical significance of the expression of key components of PD-1/PD-L1 immune checkpoint
par: Olga V. Kovaleva, et autres
Publié: (2021)